Anixa Biosciences, Inc.
Company Snapshot: Anixa Biosciences, Inc.
Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. It is developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is available at www.anixa.com.
- Nov 7 2019 Anixa Biosciences Announces Presentation at Cell Symposia: Hallmarks of Cancer
- Nov 5 2019 Anixa Biosciences Announces Patent Issued for its Breast Cancer Vaccine
- Oct 28 2019 Anixa Biosciences Names Novartis Executive Dr. Emanuele Ostuni to Scientific Advisory Board
- Oct 25 2019 Anixa Biosciences Announces Collaboration with Urology San Antonio on Cchek™ Prostate Cancer Study